A detailed history of Fortis Group Advisors, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Fortis Group Advisors, LLC holds 15 shares of BIIB stock, worth $2,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15
Previous 15 -0.0%
Holding current value
$2,397
Previous $3.48 Million 16.39%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

SELL
$212.02 - $267.71 $3,180 - $4,015
-15 Reduced 50.0%
15 $3.23 Million
Q4 2023

Mar 04, 2024

BUY
$222.59 - $267.94 $3,338 - $4,019
15 Added 100.0%
30 $7.76 Million
Q3 2023

Dec 01, 2023

BUY
$253.3 - $285.89 $3,799 - $4,288
15 New
15 $3.86 Million
Q1 2023

May 26, 2023

SELL
$256.56 - $292.34 $3,848 - $4,385
-15 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$264.77 - $305.71 $3,971 - $4,585
15 New
15 $4,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $23B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fortis Group Advisors, LLC Portfolio

Follow Fortis Group Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortis Group Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortis Group Advisors, LLC with notifications on news.